跳至主要内容
临床试验/NCT02319538
NCT02319538已完成不适用

Surgical Treatment of Hashimotos Disease. Effect on Antibodies and Clinical Symptoms.

Sykehuset Telemark2 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2012年2月13日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
150
试验地点
2
主要终点
Better outcome in Quality of Life by operation

研究概览

简要总结

The investigators have already proven that absolute total thyroidectomy gives elimination of anti-TPO antibodies. Our hypothesis is that this elimination also eliminates the typical Hashimoto symptoms, namely: Serious tiredness, increased need of sleep, pain in musculature and joints and dryness in eyes and mouth. The prerequisite for this effect is that the total thyroidectomy is meticulously performed. There exists no other treatment that can eliminate the antibodies. The study is randomized between operation and ordinary conservative medical treatment with thyroxine control and supplementation. The symptoms in both groups are evaluated by 5 different Quality of Life schemes, internationally approved.

详细描述

The study hypothesis is that elimination of anti-TPO antibodies ameliorates the typical Hashimoto symptoms like tiredness,increased need of sleep, pain in musculature and joints and dryness in eyes and mouth. It is necessary that the total thyroidectomy is meticulously performed. We have proven the effect on the antibodies, and we have also proven that the operation procedure can be performed without more complications like recurrent nerve damage and hypocalcemia. Neutrality is secured by randomization done by a neutral institution, laryngoscopy by neutral doctors and instructions filling out the QoL-schemes performed by non-biased study nurses.

The study runs for at least 18 months with controls every 6 months. Blood samples are taken and international approved QoL-schemes are filled in. In addition to the randomised main group a side group of patients fulfilling 2 of the 3 inclusion criteria are followed in parallel in order to elucidate the spontaneous development of the disease and showing critical values of antibodies making the symptoms turn up.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients referred due to typical symptoms, believed to be related to Hashimoto´s disease, but not relieved by thyroxin substitution. Optimal thyroid substitution treatment is already provided.
  • Anti-TPO>1000
  • Hypothyroidism with a need for thyroxin supplementation
  • Written informed consent by the patient - information particularly emphasising and quantifying the risk of complications (e.g. recurrent laryngeal nerve palsy). The patient should be informed by a medical endocrinologist as well as a surgeon.

排除标准

  • Patients <18 years of age.
  • Unable to comprehend information adequately to give informed consent.
  • General anaesthesiological contraindications.
  • An unexpected finding of cancer in the surgical group is not a reason for exclusion per se, but this group should be analyzed separately. It is expected that any different loading in Quality of life would bias the medically treated group.

研究组 & 干预措施

Non-surgical treatment only

No Intervention

Control arm. This arm receives standard medical hormone treatment (Thyroxine substitution) only and no surgical intervention.

Total thyroidectomy performed

Active Comparator

Surgical arm.The approach for total thyroidectomy will be a complete removal of all visible, and immunological active thyroid tissue with a high accuracy, with a special focus on three sites; 1) The angle where the recurrent laryngeal nerve enters the cricothyroid membrane, 2) The pyramidal lobe and 3) The hilus where the superior vessels are entering the field. Standard Thyroxine supplementation maintained as in the control group.

干预措施: Total thyroidectomy performed (Procedure)

结局指标

主要结局

Better outcome in Quality of Life by operation

时间窗: 18 months

The patiens are followed for 18 months with blood samples and filling in Quality of Life schemes every 6 months

次要结局

  • Lowering of antibodies (Blood samples)(18 months)

研究者

发起方
Sykehuset Telemark
申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Ivar Guldvog

Consultant

Sykehuset Telemark

研究点 (2)

Loading locations...

相似试验